NICE Technology Appraisal 694: Bempedoic acid▼ with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
The production of this Guidelines card has been commissioned and funded by Daiichi Sankyo UK.
View Bempedoic acid (Nilemdo®▼) & Bempedoic acid and ezetimibe (Nustendi®▼) prescribing and adverse event reporting information
BEM/21/0374 May 2021
The production of this Guidelines card has been commissioned by UCB Pharma Ltd.
Amgen and UCB Pharma Ltd are co-developing Evenity®.
View prescribing information and adverse event reporting
UK-P-RM-OP-2000095 December 2020
The printing of this Guidelines summary card has been commissioned by Novartis Pharmaceuticals UK Ltd. Information intended for UK healthcare professionals only.
Click here for Prescribing information and Adverse Event Reporting.
MLR ID 103903
Date of preparation: February 2021